Distribution and characteristics of VZV reactivation disease across cohorts
| . | Allogeneic HCT recipients . | Autologous HCT recipients . | |||
|---|---|---|---|---|---|
| Cohort 1 . | Cohort 2 . | Cohort 3 . | Cohort 1 . | Cohorts 2 and 3 . | |
| Number | 720 | 851 | 402 | 212 | 450 |
| First VZV reactivation disease, no. | 178 | 73 | 18 | 45 | 35 |
| Disseminated disease, N (%) | 35 (19.6) | 15 (20.6) | 2 (1.1) | 6 (13.3) | 1 (2.9) |
| Ocular zoster | 1 (0.6) | 2 (2.7) | 0 | 0 | 2 (5.7) |
| Localized zoster | 142 (79.8) | 56 (76.7) | 16 (98.9) | 39 (86.7) | 32 (91.4) |
| Months to event, median (range) | 6 (<1-24) | 13 (<1-24) | 16 (1.5-23) | 5 (<1-22) | 14 (<1-24) |
| Recurrent VZV reactivation disease* | 8 | 3 | 0 | 0 | 2 |
| Disseminated disease | 1 (12.5) | 0 | — | — | 0 |
| Localized zoster | 7 (87.5) | 3 (100) | — | — | 2 (100) |
| Months to event, median (range) | 6 (4-22) | 17 (16-21) | — | — | (12-18) |
| . | Allogeneic HCT recipients . | Autologous HCT recipients . | |||
|---|---|---|---|---|---|
| Cohort 1 . | Cohort 2 . | Cohort 3 . | Cohort 1 . | Cohorts 2 and 3 . | |
| Number | 720 | 851 | 402 | 212 | 450 |
| First VZV reactivation disease, no. | 178 | 73 | 18 | 45 | 35 |
| Disseminated disease, N (%) | 35 (19.6) | 15 (20.6) | 2 (1.1) | 6 (13.3) | 1 (2.9) |
| Ocular zoster | 1 (0.6) | 2 (2.7) | 0 | 0 | 2 (5.7) |
| Localized zoster | 142 (79.8) | 56 (76.7) | 16 (98.9) | 39 (86.7) | 32 (91.4) |
| Months to event, median (range) | 6 (<1-24) | 13 (<1-24) | 16 (1.5-23) | 5 (<1-22) | 14 (<1-24) |
| Recurrent VZV reactivation disease* | 8 | 3 | 0 | 0 | 2 |
| Disseminated disease | 1 (12.5) | 0 | — | — | 0 |
| Localized zoster | 7 (87.5) | 3 (100) | — | — | 2 (100) |
| Months to event, median (range) | 6 (4-22) | 17 (16-21) | — | — | (12-18) |
Data are number (%) of patients, unless otherwise indicated.
— indicates no entry (0 recurrents).
The occurrence of a new episode of VZV reactivation disease 1 week after discontinuation of adequate antiviral treatment and complete resolution of a preceding episode was defined as recurrent VZV reactivation disease.